These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 15616150)

  • 1. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.
    Chen C; Mireles RJ; Campbell SD; Lin J; Mills JB; Xu JJ; Smolarek TA
    Drug Metab Dispos; 2005 Apr; 33(4):537-46. PubMed ID: 15616150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.
    Matsushima S; Maeda K; Kondo C; Hirano M; Sasaki M; Suzuki H; Sugiyama Y
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1059-67. PubMed ID: 15901800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport.
    Yamazaki M; Li B; Louie SW; Pudvah NT; Stocco R; Wong W; Abramovitz M; Demartis A; Laufer R; Hochman JH; Prueksaritanont T; Lin JH
    Xenobiotica; 2005 Jul; 35(7):737-53. PubMed ID: 16316932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice.
    Chen C; Lin J; Smolarek T; Tremaine L
    Drug Metab Dispos; 2007 Oct; 35(10):1725-9. PubMed ID: 17640956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.
    Sakaeda T; Fujino H; Komoto C; Kakumoto M; Jin JS; Iwaki K; Nishiguchi K; Nakamura T; Okamura N; Okumura K
    Pharm Res; 2006 Mar; 23(3):506-12. PubMed ID: 16388406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of acid and lactone forms of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on the induction of MDR1 expression and function in LS180 cells.
    Yamasaki D; Nakamura T; Okamura N; Kokudai M; Inui N; Takeuchi K; Watanabe H; Hirai M; Okumura K; Sakaeda T
    Eur J Pharm Sci; 2009 May; 37(2):126-32. PubMed ID: 19429419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
    Neuvonen PJ; Backman JT; Niemi M
    Clin Pharmacokinet; 2008; 47(7):463-74. PubMed ID: 18563955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers.
    Liu L; Cui Y; Chung AY; Shitara Y; Sugiyama Y; Keppler D; Pang KS
    J Pharmacol Exp Ther; 2006 Jul; 318(1):395-402. PubMed ID: 16627748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans.
    Yamashiro W; Maeda K; Hirouchi M; Adachi Y; Hu Z; Sugiyama Y
    Drug Metab Dispos; 2006 Jul; 34(7):1247-54. PubMed ID: 16624871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HMG-CoA reductase inhibitors and P-glycoprotein modulation.
    Bogman K; Peyer AK; Török M; Küsters E; Drewe J
    Br J Pharmacol; 2001 Mar; 132(6):1183-92. PubMed ID: 11250868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human skeletal muscle drug transporters determine local exposure and toxicity of statins.
    Knauer MJ; Urquhart BL; Meyer zu Schwabedissen HE; Schwarz UI; Lemke CJ; Leake BF; Kim RB; Tirona RG
    Circ Res; 2010 Feb; 106(2):297-306. PubMed ID: 19940267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter.
    Wu X; Whitfield LR; Stewart BH
    Pharm Res; 2000 Feb; 17(2):209-15. PubMed ID: 10751037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors.
    Choi MK; Shin HJ; Choi YL; Deng JW; Shin JG; Song IS
    Xenobiotica; 2011 Jan; 41(1):24-34. PubMed ID: 20946088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2).
    Sasaki M; Suzuki H; Ito K; Abe T; Sugiyama Y
    J Biol Chem; 2002 Feb; 277(8):6497-503. PubMed ID: 11748225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
    Jacobson TA
    Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers.
    Shin KH; Kim TE; Kim SE; Lee MG; Song IS; Yoon SH; Cho JY; Jang IJ; Shin SG; Yu KS
    J Cardiovasc Pharmacol; 2011 Nov; 58(5):492-9. PubMed ID: 21765368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein.
    Higgins JW; Bao JQ; Ke AB; Manro JR; Fallon JK; Smith PC; Zamek-Gliszczynski MJ
    Drug Metab Dispos; 2014 Jan; 42(1):182-92. PubMed ID: 24194513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.
    Ieiri I; Higuchi S; Sugiyama Y
    Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):703-29. PubMed ID: 19442037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2).
    Lalloo AK; Luo FR; Guo A; Paranjpe PV; Lee SH; Vyas V; Rubin E; Sinko PJ
    BMC Med; 2004 May; 2():16. PubMed ID: 15125776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin.
    Jacobsen W; Kuhn B; Soldner A; Kirchner G; Sewing KF; Kollman PA; Benet LZ; Christians U
    Drug Metab Dispos; 2000 Nov; 28(11):1369-78. PubMed ID: 11038166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.